| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 08/07/2002 | EP1228031A2 Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye |
| 08/07/2002 | EP1228030A2 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 08/07/2002 | EP1228029A1 Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
| 08/07/2002 | EP1228028A1 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 08/07/2002 | EP1228027A2 3-heteroatom substituted and two carbon homologs of 15-hete and methods of use |
| 08/07/2002 | EP1228026A2 15-hydroxyeicosatetraenoic acid-related compounds and methods of use |
| 08/07/2002 | EP1227859A2 Neurophilin ligands for treating ocular conditions |
| 08/07/2002 | EP1227834A2 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
| 08/07/2002 | EP1227833A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 08/07/2002 | EP1227813A1 Reverse-turn mimetics and methods relating thereto |
| 08/07/2002 | EP1227812A2 Topical nasal treatment using desloratadine |
| 08/07/2002 | EP1227809A2 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
| 08/07/2002 | EP1039912B1 Angiostatic agents and compositions for treating glc1a glaucoma |
| 08/07/2002 | EP0888336B1 Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)p iperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
| 08/07/2002 | EP0701434B1 Preparations containing silicon dioxide to improve the taste thereof |
| 08/07/2002 | CN1362954A Sulfamato hydroxamic acid metalloprotease inhibitor |
| 08/07/2002 | CN1362952A 2-arylimino-2,3-dihydothiazoles, and their use thereof as somatostain receptor ligands |
| 08/07/2002 | CN1362947A N-cyanomethylamides as protease inhibitors |
| 08/07/2002 | CN1362883A Stable composition comprising epidermal growth factor as active ingredient |
| 08/07/2002 | CN1362875A Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues |
| 08/07/2002 | CN1362189A Nano Eight-treasure medicine and its preparation |
| 08/07/2002 | CN1362130A Nano eyesight-improving peal medicine and its preparation |
| 08/07/2002 | CN1362124A Nano eyesight-improving noble dendrobium medicine and its preparation |
| 08/07/2002 | CN1362107A Nano ear-drop oil medicine and its preparation |
| 08/07/2002 | CN1362065A Tympanitis treating powder and its prepn |
| 08/06/2002 | US6429227 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
| 08/06/2002 | US6429226 Prostaglandin derivatives with phenyl ring in omega chain; topical application |
| 08/06/2002 | US6429223 Modified forms of pharmacologically active agents and uses therefor |
| 08/06/2002 | US6429213 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 08/01/2002 | WO2002059286A2 Adenylate cyclases |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002058789A1 Ocular iontophoretic device and method of use |
| 08/01/2002 | WO2002058735A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058695A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | WO2002058679A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | WO2002058668A2 Artificial tear composition adapted to be used with contact lenses |
| 08/01/2002 | WO2002058636A2 Novel cannabimimetic ligands |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002049574A3 Method for curing child's and adolescent myopia using a spiruline preparation |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002024226A3 Photosensitisers |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002012227A3 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2001091799A3 Medicament for the treatment of immune reactions in the eye |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001082953A3 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 08/01/2002 | WO2001078654A3 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 08/01/2002 | WO2001078530A3 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001026678A9 Short segments of dap-kinase |
| 08/01/2002 | US20020103376 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 08/01/2002 | US20020103257 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 08/01/2002 | US20020103242 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103235 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103196 Stabilizing pharmaceutical composition by contacting with polymeric material containing an antioxidant; eye drops |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103180 Methods, compositions and articles for reducing or preventing the effects of inflammation |
| 08/01/2002 | US20020103167 Method of treating certain eye diseases |
| 08/01/2002 | US20020103166 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders |
| 08/01/2002 | US20020103158 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 08/01/2002 | US20020103157 Stimulation of tear secretion by administering uridine 5'-triphosphate dinucleotides, cytidine 5'-triphosphate, adenosine 5'-triphosphate or their useful analogs; enhances mucociliary clearance of nasolacrimal duct |
| 08/01/2002 | US20020103112 Wound healing and treatment of fibrosis |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102307 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435888A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 07/31/2002 | EP1226231A1 19 human secreted proteins |
| 07/31/2002 | EP1226160A2 Novel antiarrhythmic peptides |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226132A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 07/31/2002 | EP1226131A2 Isoxazolecarboxamide derivatives |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226112A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 07/31/2002 | EP1225922A1 Selective toxin expression in angiogenic endothelial cells |
| 07/31/2002 | EP1225901A2 Uses and compositions for treating platelet-related disorders using anagrelide |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |